头孢哌酮/舒巴坦联用血必净治疗急性胆囊炎的临床疗效研究

84例急性胆囊炎患者随机分为对照组和试验组,各42例;对照组给予头孢哌酮舒巴坦(3 g q8h ivgtt);试验组在对照组基础上加用血必净注射液(50 mL qd ivgtt).7天后作临床疗效评价,并观察两组的总胆红素、血清淀粉酶、白细胞计数、C-反应蛋白(CRP)、降钙素原(PCT)及肿瘤坏死因子-α(TNF-α)水平的变化.试验组临床总有效率88.05%,对照组总有效率61.90%,试验组优于对照组(P<0.05).试验组腹痛消失时间、恶心呕吐消失时间、正常饮食时间和体温恢复正常时间均小于对照组(P<0.05).试验组总胆红素、血清淀粉酶、白细胞计数、CRP、PCT及TNF-α水平均显著小于对照组(P<0.05).试验组复发率5.40%,对照组复发率30.77%,差异有统计学意义(P<0.05);两组均未发生药物不良反应.提示头孢哌酮舒巴坦联用血必净注射液治疗急性胆囊炎能显著改善患者临床症状,抑制炎性介质释放,降低总胆红素,提高疗效,降低复发率.

Clinical Efficacy of Cefoperazone Sulbactam Combined with Xuebijing Injections in the Treatment of Acute Cholecystitis

Eighty-four patients with acute cholecystitis were randomly divided into two groups: control group (n=42) and test group (n=42). Patients in the control group were given cefoperazone-sulbactam (3 g q8h ivgtt). Based on the treatment of the control group, patients in the test group were added Xuebijing in-jections (50 mL qd ivgtt). Clinical efficacy was evaluated after 7 days. In the meanwhile, before and after the treatments, total bilirubin, serum amylase, white blood cell count, C- reactive protein (CRP), procalci-tonin (PCT) and tumor necrosis factor-a (TNF-α) of the two groups were measured respectively. Effective rate in the test group (88.05%) was higher than that in the control group (61.90%), with significant differ-ence (P<0.05). The ending time of abdominal pain, nausea and vomiting and the time of diet and body temperature returned to normal in the test group were shorter than those in the control group (P<0.05). The levels of total bilirubin, serum amylase, white blood cell count, CRP, PCT and TNF-α of the test group were much lower than those of the control group (P<0.05). The recurrence rate of the test group (5.40%) was much lower than that of the control group (30.77%), with significant difference (P<0.05). There were no adverse drug reactions in both groups. The result suggested that Xuebijing injections combined with cefoper-azone sulbactam for acute cholecystitis can improve clinical symptoms, inhibit the release of inflammatory factors, reduce total bilirubin, improve clinical efficacy and reduce recurrence rate.